Introduction
Pioneering studies of Joseph Barcroft and his students drew attention to the value of high altitude as a natural laboratory for understanding the mechanisms by which intrauterine hypoxia reduces fetal growth (Barcroft, 1933; Barron et al., 1964) .
A key determinant of fetal growth is the pregnancy rise in uterine artery (UtA) blood flow, which is due, in turn, to profound changes in multiple physiological systems (Gant & Worley, 1989) . Among the greatest are the structural remodelling and alterations in vasoreactivity of the uterine vasculature that result in approximately 20% of the maternal cardiac output being directed to the utero-placental circulation by term (Osol & Moore, 2014) . Isolated vessel studies in experimental animals show that chronic hypoxia is associated with a decreased vasodilator response to flow and to pharmacological agonists in the main UtA and downstream vessels (White et al., 2000; Mateev et al., 2003; Xiao et al., 2010) , which may, in turn, contribute to the reduced UtA blood flow and altitude-associated fetal growth restriction seen in highaltitude newcomers (Zamudio et al., 1995; Julian et al., 2008) . Multigenerational highland residents (Andeans and Tibetans) are relatively protected from altitudeassociated reductions in fetal growth and have a greater pregnancy rise in UtA blood flow compared with altitude newcomers (Moore et al., 1998; Giussani et al., 2001; Moore et al., 2001; Chen et al., 2002; Julian et al., 2007; Julian et al., 2009; Soria et al., 2013) . Such protection appears due, in part, to genetic factors given that it is proportional to the degree of highland ancestry and is not the result of the woman's own duration of residence at high altitude (Bennett et al., 2008; Julian et al., 2011; Soria et al., 2013) .
Identifying the genes and signalling pathways involved in protecting native highlanders presents a novel means for addressing the mechanisms by which intrauterine hypoxia influences fetal growth. Several gene regions have been acted upon by natural selection in long-resident populations Beall et al., 2010; Bigham et al., 2010; Simonson et al., 2010; Yi et al., 2010; Alkorta-Aranburu et al., 2012) . In Andeans prominent among these are single nucleotide polymorphisms (SNPs) near PRKAA1 (adenosine monophosphate-activated protein kinase [AMPK] alpha-1) Bigham et al., 2010) . Further, the AMPK alpha-1 variants more common in Andeans are positively associated with infant birth weight as well as with key determinants of fetal growth, namely the pregnancy-associated increase in UtA diameter and the expression patterns of genes in metabolic pathways proposed to play a role in altitude-associated fetal growth restriction (Yung et al., 2012; Bigham et al., 2014) .
AMPK is a ubiquitously expressed enzyme in eukaryotes, that is stimulated by stresses that deplete cellular ATP and thus serves as a metabolic sensor for matching tissue energy demand with supply (Hardie et al., 2012) . It is comprised of three subunits (alpha, beta, gamma), each of which has multiple isoforms whose expression levels vary by tissue type (Viollet et al., 2010) . The alpha-1 and alpha-2 isoforms are the catalytic subunits and contain the Thr-172 site where AMPK is activated more than 100-fold via phosphorylation by LKB1 and other upstream kinases (Evans et al., 2009; Viollet et al., 2009) . In skeletal muscle AMPK activation promotes glucose uptake and mitochondrial biogenesis, and decreases energy demand by inhibiting the mechanistic target of rapamycin (mTOR) and switching on various catabolic enzymes (Hardie, 2011) . More recently AMPK activation has been recognized to have vascular effects, acting to stimulate endothelial nitric oxide (NO) production (Wang & Proud, 2006) as well as to regulate smooth muscle function directly (Goirand et al., 2007) . Underscoring its importance under conditions of hypoxia, AMPK activation has been implicated in the aetiology of early-onset preeclampsia (Yung et al., 2014a) cardiorespiratory responses to hypoxia (Evans, 2006) , and hypoxic pulmonary vasoconstriction (Evans et al., 2005) .
It is unknown whether AMPK activation influences UtA vasoreactivity during pregnancy and, if so, whether such effects are altered by exposure to hypoxia. We used a broad-ranging approach to address such questions in which human as well as experimental-animal tissues were studied using multiple methods. Specifically, we hypothesized that AMPK is present in UtA and placental tissue and that its expression was increased during pregnancy by exposure to hypoxia as detected using immunohistochemistry in mice and quantitative RT-PCR in previously collected human tissues. We further hypothesized that AMPK activation prompted UtA vasodilation and/or altered vasoconstrictor sensitivity to phenylephrine (PE) in vessels isolated from near-term mice, and that such effects were altered by exposure to hypoxia. To test these hypotheses we used the pharmacological AMPK agonist A769662 and compared UtA vasodilator and vasoconstrictor responses in vessels isolated from the normoxic vs. hypoxic animals. Finally, we treated vessels with the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) to determine the contribution of NO-dependent and -independent mechanisms to the effects of AMPK activation observed. We considered that such studies would improve our understanding of the mechanisms regulating maternal vascular responses to pregnancy and fetal growth under conditions of chronic hypoxia.
Methods
Ethical Approval. All mouse experiments were carried out using procedures consistent with the UK Animals Scientific Procedures Act 1986 and approved by the Local Ethics Review Committee of the University of Cambridge. Placentas were collected from human subjects who provided written informed consent to procedures approved by the University of Colorado Multiple Institutional Review Board (COMIRB, Aurora, CO, USA), the University College Hospital London (London, UK), and the Cambridge Local Research Ethics Committee.
Samples and Protocols. Female C57BL/6J mice were placed with males overnight. The presence of a copulatory plug the following morning was taken to indicate day one of pregnancy. Pregnant mice (n=31) were housed in groups of two or three in rooms with 21% O 2, 12 hr light-dark cycles and controlled temperature (21°C) and humidity (60%). They had ad libitum access to food (Rat and Mouse No.
3 Breeding, Special Diet Services, Witham, UK). At day 14 of pregnancy (term is ~ 21 days), animals were randomly assigned to normoxic or hypoxic (10% O 2 ) treatment groups. Hypoxia was achieved by placing the animals in a chamber containing a PVC isolator (PFI plastics Ltd) and a N 2 generator (N2MID60, Domnick Hunter Ltd, UK) so as to control the percent O 2 within the chamber, without changing the CO 2 levels, by altering the inflows of air and N 2 . O 2 levels were monitored using an O 2 analyser (ICA, UK) and CO 2 levels by a portable CO 2 analyser that was calibrated daily (The Electronic Workshop, Department of Physiology, Development and Neuroscience, University of Cambridge). Normoxic animals were housed in the same room that contained the chambers. Maternal weight, food and water intake were monitored daily. This was achieved in the hypoxic group via a sealed transfer box that could be opened briefly without altering O 2 levels within the main chamber.
On day 19 of pregnancy mice were euthanized by cervical dislocation. The uterus was dissected immediately, the numbers of viable fetuses and fetal reabsorptions counted, fetal and placental weights recorded, and fetal biometry taken. Both UtA were removed, placed in ice cold PBS, and processed immediately (<5 min) for either myography or immunohistochemistry. In approximately half the normoxic and hypoxic animals, one placenta whose weight was closest to the litter mean was prepared for immunohistochemistry.
Samples from human placentas were obtained from term, non-labouring women residing either at sea level (n=3) or high altitude (3100 m, n=3) as described previously (Yung et al., 2012) .
Immunohistochemistry. The murine uterine vessels were placed in ice cold PBS, cleared of adipose tissues and the uterine horn using a dissecting microscope (Leica, Germany), and fixed in 4% paraformaldehyde. The main UtA together with its 1 st and 2 nd order branches was divided into 2-3 longitudinal segments, embedded in a single paraffin block, and sectioned. Whole placentas were washed with PBS, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Paraffin-embedded sections were de-waxed, washed, prepared for antigen retrieval using 0.01 M citric buffer (pH 6.0), and incubated overnight using either primary antibody (phospho-AMPKα [Thr172] [40H9] rabbit) from Cell Signalling Technology (Hitchin, UK) diluted in 5% GS/HS in TBS or vehicle alone. The following day, the secondary antibody (anti-rabbit IgG, diluted 1:200 in 5% GS/HS) was applied, incubated for 1 hr, developed for staining using DAB and counterstained with hematoxylin. The slides were scanned using a Nanozoomer (Hamamatsu Photonics, Welwyn Garden City, UK), saved as high-resolution files, and images quantified using IPLAb software Quantitative RT-PCR. RNA from mouse (n=3) or human (n=6) placental tissue was extracted using the miRNeasy Mini Kit from Qiagen (Manchester, UK) following the manufacturer's guidelines, and the concentration determined using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Hemel Hempstead, UK). cDNA synthesis was carried out using the Transcriptor High Fidelity cDNA synthesis Kit (Roche, UK) following manufacturer instructions. For qPCR analysis, 2.5 µl of cDNA in RNase free water was made up to 25 µl with FastStart Universal SYBR Green Master (ROX, 12.5 µl, Roche), Ultra Pure Water (8 µl, SIGMA, UK) and forward and reverse primers for LKB1, AMPK alpha-1 and alpha-2 (Qiagen, UK). The sample was then centrifuged and 25 µl added to a MicroAmp TM Fast Optical 96-Well Reaction Plate (Greiner Bio-One, Stonehouse UK), the reaction plate sealed with an optical adhesive cover (Applied Biosystems, Warrington UK) and the plate centrifuged. The reaction was then run on a sequence detection system (Applied Biosystems) using AmpliTaq Fast DNA Polymerase with a 2 min initial step at 50 o C followed by a 10 min step at 95 o C, a 15 sec step at 95 o C (repeated 40 times) followed by a dissociation stage with a 15 sec step at 95 o C, and followed by a 20 sec at 60 o C and a 15 sec step at 95 o C. Negative controls included tissue aspirants for which no reverse transcriptase was added, and aspiration of extracellular medium and PCR controls. None of the controls produced any detectable amplicon, ruling out genomic or other contamination.
Myography. The murine uterine vasculature was dissected and pinned out in a dish of ice-cold Krebs solution (in mmol/L, all reagents from Sigma UK unless specified otherwise: NaCl 118.5, NaHCO 3 25, KCl 4.75, MgSO 4 .7H 2 O 1.2, KH 2 PO 4 1.2, CaCl 2 2.5, D-glucose 11.1). Using a bifocal dissecting microscope (Brunel Microscopes Ltd., UK), first-order 2 mm in length UtA segments were dissected and cleared of any connective or adipose tissue. The vessel segments were then mounted in a four-chamber, small-vessel wire myograph (Multi Wire Myograph System 620M, DMT, Denmark) by threading two wires 40 µm in diameter through the vessel lumen and attaching one to a pressure transducer and the other to a micrometer as previously described (Pulgar et al., 2011; Giussani et al., 2012) . The chamber was continually gassed with 5% CO 2 and 95% O 2 to maintain a physiological pH, and gradually heated to 37°C. Throughout the investigation, the Krebs solution was refreshed every 20 min, and the vessels allowed to re-equilibrate for at least 20 min between experiments.
UtA were normalised to 0.9 of L 13.3 kPa, and allowed to equilibrate for 20 min. Two vessels from each animal were pre-constricted with a dose of PE determined to produce 70% of the maximal constriction to PE for each vessel. The sub-maximally pre-constricted vessels were then relaxed by addition of the AMPK agonist A769662 (Tocris, USA) dissolved in DMSO in increasing concentrations (1x10 -6 M to 1x10 -4 M) at 10-min intervals, and the results from the two vessels per animal averaged. We chose A769662 because, unlike 5-amino-1-beta-D-ribofuranosyl-imidazole-4carboxamide (AICAR) or metformin, it activates AMPK directly, and not other enzymes that are responsive to AMP levels (Goransson et al., 2007) . Another advantage is that A769662, unlike AICAR, is not taken up by the adenosine transporter and therefore does not lead to the accumulation of adenosine outside cells or necessitate the use of an adenosine antagonist (Goransson et al., 2007) . A third and fourth vessel segment from each animal was also tested using increasing doses of PE (1x10 -9 M -1x10 -4 M), with this then being repeated following 20 min incubation with A769662 (1x10 -4 M) and finally repeated a third time following incubation with A769662 (1x10 -4 M) plus the NOS inhibitor L-NAME (1x10 -5 M). The finding that the third curve was consistently larger than the second provided reassurance that the response of the vessels was not deteriorating over time.
Studies were completed in vessels from a total of 17 animals.
Data and Statistical Analyses. The contractile response to PE was expressed as a percentage of the maximal constriction produced by KCl (% K max ). The curves were fitted with the best-fit line for describing the response to a given agonist. The negative logarithm to base 10 of the dose at which vessels were 50% maximallyconstricted to PE (EC 50 or pD 2 ) was used as an index of vascular sensitivity, and the area under the curve (AUC) was calculated to assess overall reactivity using Prism v6.0 (GraphPad Software, La Jolla CA). Single values were compared between normoxic and hypoxic groups using unpaired t-tests. Differences in immunostaining or mRNA expression between normoxic and hypoxic groups were assessed using one-way ANOVA with Student Neuman Keuls post hoc test. The effects of AMPK activation on PE-induced constriction were assessed using two-way ANOVA with Tukey post hoc test (Sigma Stat, Buckinghamshire, UK). Data are presented as the mean ± standard error of the mean (S.E.M.). Significance was accepted when the two-tailed p<0.05 and reported as trends when 0.05<p<0.10.
Results
Maternal and fetal characteristics. Murine maternal body weights were similar at days 1 and 14, but reduced at day 19 in the hypoxic compared with normoxic groups (Table 1) . Litter size was not reduced in the hypoxic group although there was a trend for a greater number of reabsorptions. Fetuses from hypoxic pregnancies weighed less but placental weights were similar to those seen in the normoxic group.
Fetuses from the hypoxic compared with the normoxic group had smaller crownrump lengths, biparietal diameters (BPD) and a greater BPD to body weight ratio, indicating asymmetric growth restriction (Table 1) .
Placental and birth weights were similar for the non-labouring, sea-level or high-altitude women (Table 1) , although birth weight was reduced at high altitude in the larger group of subjects from which these data were derived (Yung et al., 2012) Immunohistochemistry. The uterine vessels from normoxic mice demonstrated staining for phosphorylated (activated) AMPK in arteries of varying size. The hypoxic compared with normoxic animals had greater staining intensity with primary antibody (22.0% vs. 11.0% respectively, p<0.0001) whereas the staining intensity did not differ in the vessels from normoxic animals with and without antibody (p=0.12), indicating minimal AMPK expression ( Figure 1, left hand panels) .
Phosphorylated AMPK was also present in all regions of the mouse placenta ( Figure   1 , right hand panels). Whereas staining intensity did not differ between the JZ and LZ of the placenta from normoxic animals (p=NS), hypoxic exposure markedly increased LZ relative to JZ staining (p<0.0001).
Quantitative RT-PCR. Results from quantitative RT-PCR assays showed that mRNA for LKB1, AMPK alpha-1, and AMPK alpha-2 (as a % of -actin) were present in human and mouse placental tissue. Levels of RT-PCR products for LKB1 and both AMPK catalytic isoforms were greater in the tissues from the high-altitude compared with sea-level human placentas (Figure 2, top panel) . In sea-level mouse placentas, AMPK alpha-2 levels were higher in the labyrinthine than junctional zones (Figure 2 Myography. The internal circumference of the isolated UtA at the time of study was similar in the normoxic and hypoxic murine groups (Table 1) . There was no difference in the maximal contraction to KCl or PE, the contractile sensitivity to PE as measured by the pD 2 (Table 1) , or the relaxation response to ACh (10 -10 M to 10 -4 M, p=NS, data not shown).
A769662, an AMPK agonist, caused complete, concentration-dependent relaxation in the PE pre-constricted UtA and that relaxation was similar in the normoxic and hypoxic mice ( Figure 3A ). Inhibition of NOS by incubation with L-NAME reduced the relaxation response to A769662 by 30% but did not fully reverse it, indicating that 70% was NO-independent in both the normoxic and hypoxic groups ( Figure 3B ).
Incubation with the AMPK agonist A769662 reduced UtA contractile sensitivity to PE in both the normoxic and hypoxic mice as demonstrated by the rightward shifts in the contractile concentration-response curves ( Figure 4A-B) , with the change due to A769662 being greater in the hypoxic than normoxic groups ( Figure 4C ).
Treatment of the vessel with L-NAME increased contractile sensitivity to PE in vessels from normoxic or hypoxic mice (two-way ANOVA, both p<0.05), indicating that a portion of A769662's effect in opposing PE-induced vasoconstriction was likely due to increased NO production or activity. However, L-NAME treatment did not fully reverse A769662's effect, indicating that there was a NO-independent contribution as well. Moreover the NO-independent component was principally responsible for the greater vasodilator effect of AMPK activation seen in the vessels from hypoxic than normoxic animals ( Figure 4D ).
Discussion
Our principal findings were that AMPK was present in uterine arteries from near-term mice as well as in mouse and human placental tissue, and that AMPK expression was increased by hypoxia as judged by immunohistochemistry and mRNA expression. Consistent with the possibility that the LKB1-AMPK signalling pathway influenced vascular reactivity, we found that pharmacological activation of AMPK caused PE-preconstricted UtA from pregnant mice to relax due to both NOdependent and NO-independent mechanisms. While the vasodilator effect of AMPK activation was similar in UtA isolated from normoxic or hypoxic mice, AMPK activation more markedly opposed PE-induced constriction in the UtA from the hypoxic than the normoxic mice and this was due to NO-dependent but largely NO-independent mechanisms. We therefore concluded that AMPK activation dilates uterine arteries, particularly in response to PE-induced vasoconstriction, and that this latter effect is enhanced by hypoxic pregnancy.
AMPK activation in non-pregnant animals has chiefly been studied for its metabolic effects. Drugs such as metformin, which is widely prescribed for lowering glucose levels in individuals with type 2 diabetes, decrease hepatic glucose production by mildly inhibiting the mitochondrial respiratory chain complex I, which in turn activates AMPK . In skeletal muscle, AMPK activation promotes glucose uptake and mitochondrial biogenesis, and decreases energy demand by inhibiting the mechanistic target of rapamycin (mTOR) or by switching on the expression of various catabolic enzymes (Hardie, 2011) . More recently it has been recognized that AMPK activation also has vascular effects. Vessels express AMPK alpha-1 and alpha-2 isoforms; alpha-1 predominates in endothelial cells and both are present in vascular smooth muscle with their relative predominance varying by tissue type (Evans et al., 2005; Goirand et al., 2007; Matsumoto et al., 2008) .
AMPK activation has been shown to improve cardiac function in a rat model of chronic heart failure (Wang et al., 2011) ; to help initiate hypoxic pulmonary vasoconstriction (Evans et al., 2005) ; and to augment acetylcholine-induced relaxation in pre-constricted isolated thoracic aorta, mesenteric or resistance-sized cremaster arteries (Goirand et al., 2007; Ford & Rush, 2011) . Importantly, the vascular effects of AMPK activation are not dependent on its metabolic effects (Bradley et al., 2010) or, as is the case with AICAR, the accumulation of adenosine (Evans et al., 2005; Goirand et al., 2007; Bradley et al., 2010) but rather are due to both NO-dependent and NO-independent mechanisms; namely, increased eNOS activity and NO production (Viollet et al., 2010) , decreased superoxide and vasoconstrictor prostanoid production (Matsumoto et al., 2008; Li et al., 2010) , and direct actions in vascular smooth muscle (Goirand et al., 2007) .
Our data showing AMPK immunostaining in normoxic mouse uterine vessels and placenta tissue, and mRNA in murine and human placenta for both AMPK alpha isoforms and the upstream kinase responsible for activating AMPK, LKB1, in mouse and human placenta were consistent with prior reports showing that AMPK is expressed in placental tissue (Yung et al., 2012) . This is, however, to the best of our knowledge the first report of its presence in murine uterine vessels during pregnancy. The UtA and other uterine vessels undergo profound changes during pregnancy, enlarging their diameters as the result of structural remodelling as well as increased vasodilator responses to flow, acetylcholine and other pharmacological agonists (reviewed in (Osol & Moore, 2014) ). Such changes are attributable to effects of oestrogen and other pregnancy hormones serving to increase the production and/or activity of various vasodilators, including NO and largeconductance potassium channels (BK CA ), rather than placentation per se since the changes begin before placentation is complete, occur even in ectopic pregnancy, and are present albeit to a lesser degree in pseudo-pregnant animals (Burchell, 1967; Rosenfeld et al., 1996; van der Heijden et al., 2005; Collins et al., 2011; Hu et al., 2011) . The present report shows for the first time that uterine arteries are relaxed by AMPK activation, suggesting that activation of AMPK may be another mechanism contributing to pregnancy vasodilatation. The vasorelaxant effects of AMPK activation were due, in part, to increased NO production or activity as shown by the effect of NOS inhibition but the major portion of its vasorelaxant effect remained following NOS inhibition, indicating that additional NO-independent mechanisms are involved. One possibility is that AMPK activation reduced the production of vasoconstrictor prostanoids, similar to what has been reported in mesenteric arteries following metformin treatment in a rat model of type 2 diabetes (Matsumoto et al., 2008) . Direct effects on vascular smooth muscle cells may also be involved via actions on the RhoA-Rho associated protein kinase (Rock) pathway (Gayard et al., 2011) or via K + channels given that AMPK activation affects multiple K + channels (Andersen & Rasmussen, 2012) , including the BK CA and the ATP-sensitive potassium channel (K ATP ), previously implicated in uterine vascular responses to pregnancy and hypoxia (Zhu et al., 2013) . Thus further study is required in both nonpregnant and pregnant animals to determine whether pregnancy influences the effects of AMPK activation on UtA vasoreactivity, and the endothelial as well as vascular smooth muscle mechanisms involved.
Little is known about the effects of AMPK activation under conditions of hypoxia. Suggesting a beneficial role, Davidge and co-workers have shown that resveratrol, which works in part by activating AMPK (Hardie, 2011; Tennen et al., 2012) , administered to the mother under conditions of severe hypoxia dramatically improved fetal survival and increased placental relative to fetal weight but not fetal growth per se (Bourque et al., 2012; Banek et al., 2013) . Resveratrol treatment also increased UtA blood flow velocity and fetal weight in a catechol-O-methyltransferase knockout mouse model of fetal growth restriction, but vasodilator or vasoconstrictor responses of isolated UtA were unaffected (Poudel et al., 2013) . Resveratrol has also been shown to augment UtA blood flow during pregnancy in nonhuman primates (Roberts et al., 2014) .
We found that hypoxia in late murine pregnancy sufficient to decrease fetal growth increased the intensity of AMPK immunostaining in the labyrinthine zone, which may be more sensitive to hypoxia given its rich blood supply in contrast to the relatively hypovascularized junctional zone (Dilworth & Sibley, 2013) . AMPK alpha-2 mRNA expression was also greater in the labyrinthine than the junctional zone of the mouse placenta, suggesting that it may be the isoform involved in the greater immunostaining but differences in primer efficiency prevent comparison of LKB1, AMPK alpha-1 and alpha-2 expression levels. In humans, the levels of RT-PCR products for both AMPK alpha subunits and LKB1 were greater in the placentas from high-vs. low-altitude residents, suggesting higher basal AMPK activity and / or increased capacity to respond to metabolic stress. However, while these same placentas showed evidence of endoplasmic reticulum (ER) stress and mTOR inhibition, the ratio of P-AMPK to total AMPK was not consistently elevated in the small number (n=3) of non-labouring placentas available for study (Yung et al., 2012) . In pre-eclamptic women, the ratio of P-AMPK to total AMPK protein levels was inversely correlated with gestational age, being highest in those with the earliest onset of disease, although not higher overall in early-(<34 wk) vs. late (> 34 wk) onset pre-eclamptic or normotensive women (Yung et al., 2014b) . Thus, further studies in larger numbers of placentas are required to determine if AMPK is activated at high vs. low altitude in placental tissue.
We were interested in the effect of AMPK activation on UtA vasoreactivity under conditions of hypoxia given our prior studies indicating that the gene region containing AMPK alpha-1 has been acted upon by natural selection in Andean residents of high altitude and that the variants more common in Andeans were positively associated with birth weight, UtA diameter and alterations in the expression of genes in the mTOR pathway previously implicated in altitudeassociated fetal growth restriction Yung et al., 2012; Bigham et al., 2014) . The increased intensity of immunostaining in the mouse uterine arteries suggested that hypoxia increased AMPK abundance. However, since the antibody employed detects both alpha-1 and alpha-2 isoforms, we were not able to determine which isoforms were present in the uterine vessels.
Based on previous studies in pulmonary and uterine arteries, we expected that AMPK activation would have less vasodilator effect in the UtA isolated from the hypoxic vs. normoxic animals. In pulmonary arteries, AMPK activation under conditions of acute (< 60 min) hypoxia prompted vasoconstriction through mobilization of myocyte sarcoplasmic reticulum calcium stores via ryanodine receptors and the release of an endothelium-derived constrictor (Evans, 2006) .
Inhibitory effects of AMPK activation on Bk CA channels have also been observed, and in a manner that is splice-variant specific (Wyatt et al., 2007; Ross et al., 2011) .
It is notable, therefore, that Bk CA channels are inhibited in resistance-sized ovine uterine vessels and, in turn, reverse the normal pregnancy reduction in myogenic tone (Hu et al., 2012) . Further, we have reported that hypoxia throughout pregnancy reduced the NO-dependent UtA vasodilator response to ACh and flow in isolated guinea pig UtA (White et al., 2000; Mateev et al., 2003) . Therefore, our finding that pharmacological AMPK activation prompted similar concentration-dependent vasodilation in preconstricted UtA from normoxic and hypoxic animals was somewhat surprising. Since maximal contraction to PE tended (p=0.07) to be greater in the hypoxic than the normoxic group and in order to evaluate the relationship between AMPK activation and PE constriction more fully, we extended our study to examine the effect of AMPK activation on contractile sensitivity to PE. We found that AMPK activation markedly reduced UtA contractile sensitivity to PE in the UtA from the hypoxic compared with normoxic animals as demonstrated by a rightward shift in the contractile-response curves. The shift was greater in the vessels from the hypoxic compared to normoxic animals, and was partly reversed by treatment with the NOS inhibitor L-NAME, suggesting a role for NO in opposing PE-induced of constriction. While we cannot rule out the possibility that hypoxic exposure increased NO sensitivity, this appeared unlikely given that the relaxation in response to ACh or A769662 was not greater in the UtA from the hypoxic compared to normoxic animals. In addition, even though the NO component was larger in the hypoxic group, the major portion of the greater reduction in contractile sensitivity to PE was NO-independent. We therefore concluded that greater AMPK activation under conditions of hypoxic pregnancy opposes PE-induced vasoconstriction, thus perhaps serving as a compensatory mechanism for maintaining uterine artery blood flow.
Further studies are required for determining the mechanisms by which AMPK activation opposes PE-induced vasoconstriction and whether similar effects of AMPK activation are observed when hypoxia is present throughout gestation such as is the case in residents of high altitude.
The strengths of our study were its broad-ranging design in which human as well as murine tissues were examined following exposure to normoxia and either shorter-or longer-term hypoxia. Further, multiple methods were used to evaluate the effects of AMPK activation and hypoxia; namely, immunohistochemistry, quantitative RT-PCR and myography. Our results, however, were limited by use of a single AMPK activator. While A769662, unlike other agonists, activates AMPK directly (Goransson et al., 2007) , it too has indirect effects by, for example, inhibiting the sodium pump (Benziane et al., 2009 ). While we used only one agonist, our results were similar to those obtained using metformin, AICAR or exercise to activate AMPK, and thus suggested that the responses observed were the result of AMPK activation and not some other effect of the agonist employed (Goirand et al., 2007; Ford & Rush, 2011; Wang et al., 2011; Kroller-Schon et al., 2012) but additional studies using other agonists are required to confirm the mechanisms of A769662 action. Further studies are also needed using western blot to document AMPK activation, knock-out mice for clarifying the roles of the AMPK alpha-1 and AMPK alpha-2 isoforms, and pair-fed animals to control for the lesser maternal weight gain seen during the period of hypoxic exposure in the present report. The possible effect of duration of hypoxic exposure also requires evaluation since the late-pregnancy onset employed here does not parallel the circumstances of residence at high altitude where hypoxia is present throughout gestation but, on the other hand, it does likely resemble that occurring with pre-eclampsia.
In summary, AMPK is present in maternal uterine vessels as well as in placental tissues, and its abundance increased by short-as well as longer-term hypoxia as indicated by greater immunostaining in uterine vessels from pregnant mice and increased expression of both catalytic AMPK subunits in murine and human placenta. This is, to our knowledge, the first report that pharmacological AMPK activation prompts vasodilatation in UtA via both NO-dependent and NOindependent mechanisms, and that exposure to chronic hypoxia sufficient to restrict fetal growth markedly augmented the ability of AMPK activation to oppose PEinduced vasoconstriction. Together with prior reports that genetic variation near AMPK is related to increased UtA blood flow and maintenance of fetal growth in high-altitude adapted Andeans, we speculate that AMPK activation may be helping to maintain utero-placental blood flow and thereby limit cellular energy depletion. In addition to its role as a metabolic sensor, AMPK may be a key link between maternal metabolic and cardiovascular responses to pregnancy and the regulation of fetal growth. 
